In a head-to-head comparison of the 2 drugs, it was concluded that ixekizumab showed superior efficacy to adalimumab, based on simultaneous achievement of ACR50 and PASI100 responses in week 24, in biologic-naïve patients with active psoriatic arthritis (PsA) and skin disease. Greater improvements with ixekizumab versus adalimumab were also attained in individual PsA domains and composite treat-to-target outcomes.
TNF inhibitors (TNFi) like adalimumab are frequently prescribed in patients receiving biologic treatment. However, a significant number of patients with PsA have insufficient response or become intolerant to TNFi therapy . Therefore, therapies with an alternative mechanism of action and with long-term efficacy and safety are important for patients with PsA. IL-17A is a pro-inflammatory cytokine involved in the pathophysiology of PsA . Ixekizumab is a high affinity monoclonal antibody that selectively targets IL-17A .
Dr Philip Mea...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Cohort Study Shows Improvement During 25 Years of RA Treatment Next Article
What Is New in Osteoarthritis »
Table of Contents: EULAR 2019
Osteoarthritis and Osteoporosis
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.